Using digital health technology to support exercise in people with mitochondrial disease
MITO-VATION - Feasibility of a Technology-supported Structured Home Exercise Program in Mitochondrial Disease?
NA · Neuroscience Research Australia · NCT06535646
This study is testing if a home exercise program supported by digital technology can help people with mitochondrial disease stick to their workouts.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Neuroscience Research Australia (other) |
| Locations | 1 site (Sydney, New South Wales) |
| Trial ID | NCT06535646 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the feasibility and acceptability of a structured home exercise program for individuals with mitochondrial disease, supported by digital health technology. Participants will be remotely monitored over an 8-week period while using a customized exercise program and a smartwatch to track their activity. The study will assess enrollment rates, dropout rates, compliance with the exercise regimen, and the acceptability of the intervention through questionnaires. The goal is to determine if digital health solutions can effectively enhance exercise adherence in this population.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a confirmed diagnosis of a primary mitochondrial disease who can walk for at least 6 minutes.
Not a fit: Patients who are wheelchair-bound, non-English speaking, or have significant co-morbidities that affect adherence or safety may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could improve physical activity levels and overall health outcomes for patients with mitochondrial disease.
How similar studies have performed: While the use of digital health technology in exercise programs is gaining traction, this specific approach for mitochondrial disease is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥18 years of age * Have a confirmed diagnosis of a PMD * Be able to walk a minimum of 6 minutes with or without rest * Provide written informed consent and * Willingness and ability to comply with the study procedures * Own a smart phone and be willing to download 2 apps * internet access/telehealth app Exclusion Criteria: * Have atrial fibrillation or untreated symptomatic cardiac arrhythmia * Non-English speaking * Are pregnant * Are wheelchair bound * Have visual acuity less than 6/60 (Snellen Test) * Other co-morbidities such as severe osteoarthritis, balance impairment, chronic obstructive pulmonary disease, cognitive impairment, depression and anything else that would impact on participant adherence, participant safety or interpretation of results.
Where this trial is running
Sydney, New South Wales
- Neuroscience Research Australia — Sydney, New South Wales, Australia (RECRUITING)
Study contacts
- Principal investigator: Carolyn M Sue, MBBS, PhD, FRACP — Professor and Director, Kinghorn Chair, Neurodegeneration at NeuRA and Director of Neurosciences at POWH
- Study coordinator: Jeremey T Horne, Physiotherapy
- Email: j.horne@neura.edu.au
- Phone: +61293991835
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Mitochondrial Diseases